Head and Neck Cancer | University of Iowa Clinical Research and Trials

Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

BTCRC-HN17-111: Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma

Cancer Internal Medicine Head and Neck Cancer Adult Subjects Female Subjects Male Subjects

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.